




Alzheimer's Drug Therapy Initiative

RESEARCH OVERVIEW

Information for Clinicians



The Alzheimer's Drug Therapy Initiative's Program of Research was developed by nationally-renowned researchers and experts in the treatment of Alzheimer's disease. Over a three-year period, the data from this research will help to clarify who benefits most from treatment with cholinesterase inhibitors and provide clinical and resource utilization data not otherwise available, including the potential impact on care providers.

Using Information for Research Purposes

All procedures for collecting, moving and storing data are reviewed and approved by the ethics committees of the University of British Columbia and the University of Victoria. The sharing of information with the Ministry of Health Services is governed by the *Freedom of Information and Protection of Privacy Act* and is overseen by the Ministry's Office for eHealth Privacy, Security and Legislation.

Voluntary Participation

Three projects involve interviews with patients and/or caregivers and require their written consent.

Analysis of Anonymous Information

All Personal Health Numbers and Medical Services Plan numbers are replaced with codes specifically developed for the studies to ensure anonymity.

The Five Projects

These projects all have ethics approval from the universities involved. The first two projects use anonymous data to evaluate the Alzheimer's Drug Therapy Initiative (ADTI). The remaining three projects involve personal interviews with subsets of patients and caregivers, with their written consent.

Utilization and Cost Project: Among individuals diagnosed with Alzheimer's disease and related illnesses, what is the change in their use and the associated costs of health services before, during and after the ADTI?

Clinical Epidemiological Project: Comparing patients with and without ADTI coverage, what are the different patterns of health services and medication use, including frequency and reasons for switching or stopping?

Seniors' Medication Study (SMS): Among patients with an 'indeterminate response' to the medication—those who neither improve or deteriorate—what are the benefits of continuing, switching or stopping treatment? Requires physician, caregiver and patient participation.

Caregiver Study: From the perspective of family caregivers, what are the benefits and limitations of cholinesterase inhibitors for both patients and caregivers? Requires caregiver participation only.

Clinically Meaningful Assessment of Treatment (CLIMAT) & Overall Patient Assessment Rating (OPAR): What is the difference in response patterns of people who respond to treatment, do not respond or show no clear response? This study applies the CLIMAT, a new clinical scale, to determine the clinically meaningful responses to treatment with cholinesterase inhibitors.

To learn how you can participate in the Studies, please call
1 866 511-2594
(ALZH)

Program of Research Investigators:

Neena Chappell
Malcolm Maclure



Lynn Beattie
Robin Hsiung
Kiran Rabheru
Claudia Jacova
Philip Lee



The Alzheimer's Drug Therapy Initiative is the result of collaboration between the Ministry of Health Services, the Alzheimer Society of B.C., the University of British Columbia, the University of Victoria's Centre on Aging, drug manufacturers, clinical experts, researchers and practising clinicians.